Comparing Stelara vs. Remicade for Ulcerative Colitis
Treatments studied
Part of Digestive system clinical trials.
This trial is comparing two biologic medicines, ustekinumab (Stelara) and infliximab (Remicade), to see which one works better for moderate to severe ulcerative colitis. It is for people who have never taken a biologic before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have moderate to severe ulcerative colitis (confirmed by a scope test)
- You have never taken a biologic medicine (like Remicade or Stelara) for your colitis
- You have not had infliximab or ustekinumab before
- You do not have serious heart, lung, liver, kidney, or brain conditions, active tuberculosis, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
This study compares four newer biologic medications (infliximab, filgotinib, vedolizumab, and ustekinumab) to find which works best as a first biologic treatment for ulcerative colitis that hasn't responded well to standard drugs. It aims to help doctors choose the right biologic for each patient.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study looks at how well different biologic medications work for people with moderate to severe ulcerative colitis or Crohn's disease after one year of treatment. The goal is to see which treatment helps the gut heal best.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.